NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal (Committee A) meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 6 May 2021, 9:30am – 11:45am

**Location:** via Zoom

## Committee members present:

1. Dr Jane Adam (Chair) Present for all items
2. Dr Brian Shine (Vice Chair) Present for all items
3. Professor Abdallah Al-Mohammad Present for all items
4. Mr Peter Baker Present for all items
5. Mr Richard Ballerand Present for all items
6. Dr Andrew Champion Present for all items
7. Dr Justin Daniels Present for all items
8. Dr Steve Edwards Present for all items
9. Dr Rita Faria Present for all items
10. Dr Rishi Hazarika Present for all items
11. Dr Michael Holmes Present for all items
12. Ms Sumithra Maheswaran Present for all items
13. Ms Sarah Parry Present for all items
14. Ms Becky Pennington Present for all items
15. Ms Pamela Rees Present for all items
16. Dr Stephen Sharp Present for all items

## NICE staff present:

Janet Robertson, Associate Director Present for all items

Thomas Feist, Project Manager Present for all items

Mary Hughes, Technical Advisor Present for items 1 to 4

Sana Khan, Technical Analyst Present for items 1 to 4

Zoe Charles, Technical Analyst Present for all items

Lucasz Grodzicki, Technical Lead (Contractor YHEC) Present for all items

Olivia Havercroft, Senior Medical Editor Present for items 1 to 4

Ria Skelton, Senior Medical Editor Present for items 5 and 6

Adam Storrow, Resource Impact Team Present for all items

Emily Eaton Turner, HTA Adviser Present for all items

Ella Livingstone, Technical Advisor Present for all items

Catherine Pank, Assistant Project Manager Present for items 5 and 6

Victoria Hall, Coordinator Present for items 1 to 4.1 and 5.1

Rosalee Mason, Coordinator Present for items 1 to 4.1 and 5.1

Mira Patel, Coordinator Present for all items

Marcia Miller, Administrator Present for items 1 to 4

Sophie McHugh, Administrator Present for items 5 and 6

Hollie Kemp, Apprentice Present for items 5 and 6

## External group representatives present:

Marta Soares, Senior Research Fellow, [University of York](http://niceplan2/Appraisals_TestLive/Stakeholders17.aspx?ACID=1419) Present for items 1 to 4.1

Mark Simmonds, Senior Research Fellow, [University of York](http://niceplan2/Appraisals_TestLive/Stakeholders17.aspx?ACID=1419) Present for items 1 to 4.1

James Mahon, Health Economist, Liverpool Reviews Present for item 5.1

Janette Greenhalgh, Senior Research Fellow, Liverpool Present for item 5.1

Reviews

## Observers present:

Lucy Ingram, Administrator, NICE Present for items 1 to 4.1

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Professor Khalida Ismail, Professor G.J. Melendez-Torres, Dr Alice Turner, Mr Min Ven Teo and Dr Roger Whittaker.

### News and announcements

* 1. None.

1. Minutes from the last meeting

3.1. The committee approved the minutes of the committee meeting held on 7 April 2021.

### Appraisal of Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

* 1. Part 1 – Open session
     1. The chair welcomed the external group representatives, members of the public and company representatives from Novartis Pharmaceuticals.
     2. The chair asked all committee members, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Prior to the meeting, Mr Dominic Pivonka, Committee Member, declared direct financial interests as his employer, AbbVie, is a comparator company (adalimumab) for this treatment, and has another treatment recently licensed for ankylosing spondylitis (upadacitinib). It was agreed that this declaration would prevent Mr Pivonka from participating in this section of the meeting and he was asked to leave the meeting for the duration of the item.
* Dr Rita Faria, committee member, declared indirect interests as she works at the same university as the Evidence Review Group for this appraisal. She had no knowledge or input into this appraisal prior to it being discussed at committee. It was agreed that this declaration would not prevent Dr Faria from participating in this section of the meeting.
* Professor Abdallah Al-Mohammad, committee member, declared a direct financial interest as he attended an advisory board with Novartis in October 2019, related to the publication of the PARAGON study. This study was in an unrelated disease area. Professor Al-Mohammad declared a further direct financial interest as he received honoraria in July 2020, to give a presentation to Novartis staff on heart failure. It was agreed that these declarations would not prevent Professor Al-Mohammad from participating in this section of the meeting.
* No further conflicts of interest were declared for this item.
  + 1. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
  1. Part 2 – Closed session (company representatives, external group representatives and members of the public were asked to leave the meeting)
     1. The committee discussed confidential information submitted for this item.
     2. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

### Appraisal of Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

* 1. Part 1 – Open session
     1. The chair welcomed the external group representatives, members of the public and company representatives from Eli Lilly and Company.
     2. The chair asked all committee members, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Prior to the meeting, Mr Dominic Pivonka, Committee Member, declared direct financial interests as his employer, AbbVie, is a comparator company (adalimumab) for this treatment, and has another treatment recently licensed for ankylosing spondylitis (upadacitinib). It was agreed that this declaration would prevent Mr Pivonka from participating in this section of the meeting and he was asked to leave the meeting for the duration of the item.
* Professor Abdallah Al-Mohammad, committee member, declared a direct financial interest as he attended an advisory board with Novartis in October 2019, related to the publication of the PARAGON study. This study was in an unrelated disease area. Professor Al-Mohammed declared a further direct financial interest as he received honoraria in July 2020, to give a presentation to Novartis staff on heart failure. It was agreed that these declarations would not prevent Professor Al-Mohammad from participating in this section of the meeting.
* No further conflicts of interest were declared for this item.
  + 1. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
  1. Part 2 – Closed session (company representatives, external group representatives and members of the public were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
     2. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

### Date of the next meeting

The next meeting of the Technology Appraisal (Committee A) will be held on Tuesday 8 June 2021 and will start promptly at 9:30am.